English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/203506
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Mapping Bromodomains in breast cancer and association with clinical outcome

AuthorsPérez-Peña, Javier; Páez, Raquel; Nieto-Jiménez, Cristina; Corrales-Sánchez, Verónica; Galán-Moya, Eva María; Pandiella, Atanasio CSIC ORCID CVN ; Győrffy, Balázs; Ocaña, Alberto
KeywordsBreast cancer
Cancer epigenetics
Issue Date2019
PublisherSpringer Nature
CitationScientific Reports 9: 5734 (2019)
AbstractA specific family of proteins that participate in epigenetic regulation is the bromodomain (BRD) family of proteins. In this work, we aimed to explore the expression of the BRD family at a transcriptomic level in breast cancer, and its association with patient survival. mRNA level data from normal breast and tumor tissues were extracted from public datasets. Gene set enrichment analysis (GSEA) was performed to identify relevant biological functions. The KM Plotter Online tool was used to evaluate the relationship between the presence of different genes and patient clinical outcome. mRNA level data from HER2+ breast cancer patients sensible and resistant to trastuzumab were also evaluated. The BRD family was an enriched function. In HER2 positive tumors the combined analyses of BRD2, BAZ1A, TRIM33 and ZMYND8 showed a detrimental relapse free survival (RFS). Similarly, the combined analysis of BRD2, BAZ1A, PHIP, TRIM33, KMT2A, ASH1L, PBRM1, correlated with an extremely poor overall survival (OS). The prognosis was confirmed using an independent dataset from TCGA. Finally, no relation between expression of BRD genes and response to trastuzumab was observed in the HER2 population. Upregulation of some BRD genes is associated with detrimental outcome in HER2 positive tumors, regardless trastuzumab treatment.
Description© The Author(s) 2019.
Publisher version (URL)http://dx.doi.org/10.1038/s41598-019-41934-3
URIhttp://hdl.handle.net/10261/203506
DOIhttp://dx.doi.org/10.1038/s41598-019-41934-3
E-ISSN2045-2322
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Mapping_Perez_Pena_Art2019.pdf5,56 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.